Olmesartanum Medoxomilum, Amlodipinum, Hydrochlorothiazidum shortage — LV supply status & alternatives

Olmesartanum Medoxomilum, Amlodipinum, Hydrochlorothiazidum

—

In supply · Australia

Gaduar

In supply · 🇦🇺 Australia · short in🌐 LV

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Olmesartanum Medoxomilum, Amlodipinum, Hydrochlorothiazidum

Brand names	Gaduar

Therapeutic category	Auto-created by ZVA — Medicinal Product Availability Register (Latvia) scraper

Controlled substance	No

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Verified timeline regulator events

🌐 24 Oct 2025

medium reported

🌐 9 Oct 2025

medium reported

🌐 15 Nov 2024

medium reported

🌐 18 Sept 2024

medium reported

🌐 9 May 2024

medium reported

🌐 3 Apr 2018

medium reported

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.